Their "Homeostasis as a proportional–integral control system" study, published in Nature Digital Medicine in 2020, was also based on mathematical modeling to determine some of the underlying changes in how glucose is regulated. These findings are the latest in Klick’s ongoing work in the diabetes space. "Early detection and intervention is critical in the management of Type 2 diabetes, so our method has the potential to have a significant impact on the lives of millions of people worldwide." "This new method of analysis is a major step forward in the prevention and management of diabetes," Fossat said. "What was most surprising is that 20 percent of participants, who were assessed using the standard screening tools for diabetes and cleared as healthy by a physician, were then found to have impaired glucose homeostasis–reinforcing it is now possible to provide an earlier, more accurate and sensitive assessment of people’s diabetic status," said Yan Fossat, Vice President of Klick Labs. After applying the mathematical model, patients were then re-classified into two groups based on their glucose homeostasis parameters: effective or impaired. Participants were diagnosed diabetic, pre-diabetic, or healthy, according to guidelines outlined by the American Diabetes Association.
CGM FINDINGS FULL
"We found a similar pattern in patients with IGH, albeit those patterns were more like gentle waves than dramatic peaks, but intervention on this population could limit the likelihood of progression to full diabetes."Ī total of 384 people were equipped with a CGM for the study and assessed by a physician over a two-week time period. "For people with diabetes, blood glucose levels can rise and fall like a wild roller-coaster ride with steep drops and peaks," said Jaycee Kaufman, study lead author and research scientist at Klick Labs. When they applied their patented mathematical method to data obtained from continuous glucose monitors (CGMs), scientists found about one in five study participants, considered healthy by medical standards, actually had glucose metabolism similar to those with prediabetes.
In findings published today in Mayo Clinic Proceedings: Digital Health, researchers outlined a new method of analysis that flags a precursor to prediabetes called impaired glucose homeostasis (IGH). NEW YORK & TORONTO, May 24, 2023-( BUSINESS WIRE)-Scientists at Klick Labs have developed a new way to catch the earliest signs the human body is failing to control blood glucose levels, before it reaches prediabetic levels in patients. CGM or fructosamine could thus complement HbA1c in obtaining more accurate glycemic control in this patient group.Ĭontinuous glucose monitoring Diabetic nephropathy Fructosamine Hemodialysis Hemoglobin A1c.Klick Labs develops new method to flag earliest signs of Type 2 diabetes using CGM data Fructosamine is unaffected by the factors affecting HbA1c and appears to be more accurate for glycemic monitoring. The underestimation represents a clinical challenge in optimizing glycemic control in the HD population. HbA1c evaluated by CGM underestimates plasma glucose levels in patients receiving HD. Adjusted for mean sensor glucose, HbA1c was lower in the HD group (-7.3 mmol/mol, 95% CI: -10.0-) than in the control group (p < 0.001), with no difference detected for fructosamine (p = 0.64). In the HD group, mean sensor glucose was 1.4 mmol/L (95% confidence interval : 1.0-1.8) higher than the eMPGA1c, whereas the difference for controls was 0.1 mmol/L (95% CI: -0.1- p < 0.001). HbA1c (mmol/mol), the estimated mean plasma glucose from HbA1c (eMPGA1c ) and fructosamine (μmol/L) was measured at week 17 and compared with mean sensor glucose levels from CGM. CGM (Ipro2®, Medtronic) was performed 5 times for periods of up to 7 days (with 4-week intervals) during a 16-week period. Thirty patients in the HD group and 36 patients in the control group (T2D and an estimated glomerular filtration rate >60 mL/min/1.73 m2) completed the study period of 17 weeks. To assess accuracy, we compared HbA1c and fructosamine levels with interstitial glucose measured by continuous glucose monitoring (CGM) in patients with T2D receiving HD. The accuracy of hemoglobin A1c (HbA1c) as a glycemic marker in patients with type 2 diabetes (T2D) receiving hemodialysis (HD) remains unknown.
0 kommentar(er)
